|
|
Volumn 92, Issue 3, 2000, Pages 190-192
|
|
Bone marrow experts are still debating the value of purging.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CD19 ANTIGEN;
CD20 ANTIGEN;
CD34 ANTIGEN;
LEUKOCYTE ANTIGEN;
MONOCLONAL ANTIBODY;
RITUXIMAB;
ARTICLE;
B CELL LYMPHOMA;
B LYMPHOCYTE;
BONE MARROW PURGING;
CLINICAL TRIAL;
HUMAN;
IMMUNOLOGY;
METHODOLOGY;
T LYMPHOCYTE;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD;
ANTIGENS, CD19;
ANTIGENS, CD20;
ANTIGENS, CD34;
ANTINEOPLASTIC AGENTS;
B-LYMPHOCYTES;
BONE MARROW PURGING;
CLINICAL TRIALS;
HUMANS;
LYMPHOMA, B-CELL;
T-LYMPHOCYTES;
MLCS;
MLOWN;
|
|
EID: 0034594508
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.3.190a Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
